Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.
Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.
复制标题
根据药房索赔数据测量的基于人群的局部青光眼药物的持续率。
DOI：
--
复制
发表时间：
2002
期刊：
影响因子：
--
通讯作者：
E. Mozaffari
中科院分区：
文献类型：
--
作者：
Samaresh Dasgupta;V. Oates;B. Bookhart;B. Vaziri;G. Schwartz;E. Mozaffari
背景
坚持药物治疗反映了许多因素，包括患者对治疗引起的不良事件的耐受性，以及临床医生对药物在降低眼压方面的有效性的满意程度。
客观化
这项研究通过评估停药和改变治疗的比率来评估作为初始治疗的局部青光眼药物的持久性。
方法
一项回溯性队列研究使用了来自3个不同地理位置的医疗保健计划的药房索赔数据。新治疗的年龄在65岁以下的青光眼患者是根据12个月期间最初的青光眼药物填充情况来选择的。对患者进行持续性跟踪，定义为停止或改变(改变或增加)最初的青光眼治疗；停止治疗也被评估为单独的终点。
结果
总共有1330名患者(随访1126人年)符合资格标准。与拉坦前列素使用者相比，开始接受其他局部单一疗法的患者更有可能停止或改变治疗，而开始接受其他局部单一疗法的患者比使用拉坦前列素的患者更有可能停止治疗。
结论
基于人群的数据表明，拉坦前列素与其他流行的眼部降压药相比，提供了更好的持久性。
BACKGROUND
Persistency with drug therapy reflects a number of factors, including patient tolerability of adverse events resulting from therapy and clinician satisfaction with the medication's effectiveness in reducing intraocular pressure.
OBJECTIVE
This study assesses persistency with topical glaucoma medications administered as initial therapy by evaluating rates of discontinuation and change in therapy.
METHODS
A retrospective cohort study was conducted using pharmacy claims data from 3 geographically diverse healthcare plans. Newly treated glaucoma patients younger than 65 years of age were selected based on an initial glaucoma medication fill during a 12-month period. Patients were followed for persistency, defined as discontinuation or change (switch or add-on) of initial glaucoma therapy; discontinuation of therapy was also evaluated as a separate end point.
RESULTS
In all, 1330 patients (followed for 1126 person-years) met the eligibility criteria. Compared with latanoprost users, patients initiated on other topical monotherapies were more likely to discontinue or change therapy, and patients initiated on other topical monotherapies were more likely than latanoprost users to discontinue therapy.
CONCLUSION
Population-based data indicate that latanoprost offers superior persistency compared to agents from other popular classes of topical ocular hypotensives.